PDGFR

Inhibitory Selectivity

Catalog No.	Inhibitor Name	PDGFR	PDGFRα	PDGFRβ	Other
A10001	Sorafenib Tosylate	**		**	Raf-1,VEGFR2/Flk1,B-Raf
A10468	Imatinib Mesylate				c-Kit,v-Abl
A10880	Sunitinib Malate			****	FLT3,Kit,VEGFR2
A10080	Ponatinib		****		Abl,VEGFR2,FGFR1
A10103	Axitinib		***	****	VEGFR1/FLT1,VEGFR2/Flk1,VEGFR3
A10259	Imatinib	**			c-Kit,v-Abl
A10137	Nintedanib		**	**	VEGFR3,VEGFR2,LCK
A10699	Pazopanib HCl	**			VEGFR1,VEGFR2,VEGFR3
A11411	Dovitinib		*	***	FLT3,c-Kit,FGFR1
A10025	Linifanib			**	VEGFR1/FLT1,CSF-1R,FLT3
A11052	Crenolanib		****	****
A10558	Masitinib		*	*	Kit,Lyn B,Abl1
A10101	Tivozanib		***	**	VEGFR2,VEGFR3,EphB2
A10610	Amuvatinib		***		c-Kit (D816H),FLT3 (D835Y)
A10608	Motesanib Diphosphate	**			VEGFR1,VEGFR2,VEGFR3
A10953	Orantinib			***	FGFR1,Flk1
A11350	CP-673451		***	****	c-Kit,VEGFR2,VEGFR1
A10502	Ki8751		**		VEGFR2,c-Kit,FGFR2
A10903	Telatinib		***		c-Kit,VEGFR3,VEGFR2
A11207	PP121	****			Hck,VEGFR,mTOR
A11518	Pazopanib	**			VEGFR1,VEGFR2,VEGFR3
A10504	KRN 633		*	*	VEGFR3,VEGFR2,VEGFR1
A10198	Dovitinib Dilactic Acid		*	***	FLT3,c-Kit,VEGFR3/FLT4
A11753	MK-2461			***	c-Met (M1250T),c-Met (Y1235D),c-Met (Y1230H)
A14156	AZD2932			****	Flt3,VEGFR-2,c-Kit
A15062	DCC-2618		***	***	c-Kit

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Quick View
Regorafenib monohydrate

Catalog No. A15218
Quick View

添加到收藏
Tyrosine kinase 抑制剂

Regorafenib monohydrate是VEGFR1/VEGFR2/VEGFR3/PDGFRβ/Kit/RET和Raf-1的多靶点抑制剂，IC50分别为13 nM/4.2 nM/46 nM/22 nM/7 nM/1.5 nM和2.5 nM。了解更多

Bulk Inquiry
Quick View
Regorafenib (BAY 73-4506)

Catalog No. A10250
Quick View

添加到收藏
VEGFR 抑制剂

Regorafenib (BAY 73-4506)是一种多激酶抑制剂，IC50为17、40和69 nM c-KIT，VEGFR2，B-Raf。Regorafenib（BAY 73-4506）是一种针对肿瘤及其脉管系统的口服生物利用型多激酶抑制剂。了解更多

Product Citations (9)

Bulk Inquiry Free Sample
- Paula Sagmeister, .et al. Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis, J Hepatocell Carcinoma, 2022, Jul 9;9:595-607 PMID: 35845819
- Majid Momeny, .et al. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells, Life Sci, 2021, Dec 15;287:120100 PMID: 34715143
- Jindal A, .et al. Milciclib and sorafenib synergistically downregulate c-Myc to suppress tumor growth in an orthotopic murine model of human hepatocellular carcinoma, J Transl Sci, 2020, 7: 1-10
- Makoto Koyama, .et al. Low-dose trametinib and Bcl-xL antagonist have a specific antitumor effect in KRAS-mutated colorectal cancer cells, Int J Oncol, 2020, Sep 2 PMID: 32901840
- Mariko Fujisawa, .et al. Involvement of the Interferon Signaling Pathways in Pancreatic Cancer Cells, Anticancer Res, 2020, 40: 4445-4455 PMID: 32727774
- Majid Momeny, .et al. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells, Eur J Pharmacol, 2020, 882:173298
- Sunil Kumar Yadava, .et al. Low Temperature, Easy Scaling Up Method for Development of Smart Nanostructure Hybrid Lipid Capsules for Drug Delivery Application, Colloids Surf B Biointerfaces, 2020, Mar 2;190:110927 PMID: 32169777
- Takeshi Uenaka, .et al. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease, Hum Mol Genet, 2018, Nov 15; 27(22): 3974-3985 PMID: 30137437
- Yi Xu, .et al. Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2, Free Radic Biol Med, 2016, Jul; 96: 67-77 PMID: 27101738